161 related articles for article (PubMed ID: 12066219)
1. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells.
Mukai M; Kanzaki A; Chen ZS; Miyashita H; Sumizawa T; Furukawa T; Haraguchi M; Takebayashi Y; Takamatsu H; Akiyama S
Oncol Rep; 2002; 9(4):839-44. PubMed ID: 12066219
[TBL] [Abstract][Full Text] [Related]
2. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
3. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
4. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
5. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
6. Factors involved in the cisplatin resistance of KCP‑4 human epidermoid carcinoma cells.
Oiso S; Takayama Y; Nakazaki R; Matsunaga N; Motooka C; Yamamura A; Ikeda R; Nakamura K; Takeda Y; Kariyazono H
Oncol Rep; 2014 Feb; 31(2):719-26. PubMed ID: 24317338
[TBL] [Abstract][Full Text] [Related]
7. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
[TBL] [Abstract][Full Text] [Related]
8. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
[TBL] [Abstract][Full Text] [Related]
9. Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells.
Oiso S; Ikeda R; Nakamura K; Takeda Y; Akiyama S; Kariyazono H
Oncol Rep; 2012 Jul; 28(1):27-32. PubMed ID: 22562377
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*).
Moorehead RA; Armstrong SG; Rainbow AJ; Singh G
Cancer Chemother Pharmacol; 1996; 38(3):245-53. PubMed ID: 8646799
[TBL] [Abstract][Full Text] [Related]
11. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
13. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
Wu X; Fan W; Xu S; Zhou Y
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5874-9. PubMed ID: 14676109
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
15. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.
Ferry KV; Hamilton TC; Johnson SW
Biochem Pharmacol; 2000 Nov; 60(9):1305-13. PubMed ID: 11008124
[TBL] [Abstract][Full Text] [Related]
16. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Mutoh M; Sumizawa T; Furukawa T; Haraguchi M; Tani A; Saijo N; Kondo T; Akiyama S
Exp Cell Res; 1998 May; 240(2):312-20. PubMed ID: 9597004
[TBL] [Abstract][Full Text] [Related]
17. A novel function of emodin: enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells.
Chang LC; Sheu HM; Huang YS; Tsai TR; Kuo KW
Biochem Pharmacol; 1999 Jul; 58(1):49-57. PubMed ID: 10403518
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Lin X; Howell SB
Mol Cancer Ther; 2006 May; 5(5):1239-47. PubMed ID: 16731756
[TBL] [Abstract][Full Text] [Related]
19. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
20. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]